NCT00117117View on ClinicalTrials.gov

A Study to Assess Symptom Burden in Subjects With Nonmyeloid Malignancies Receiving Chemotherapy and Aranesp®

PHASE4CompletedINTERVENTIONAL
Enrollment

2,423

Participants

Timeline

Start Date

September 30, 2002

Study Completion Date

December 31, 2003

Conditions
Anemia
Interventions
DRUG

Aranesp

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY

NCT00117117 - A Study to Assess Symptom Burden in Subjects With Nonmyeloid Malignancies Receiving Chemotherapy and Aranesp® | Biotech Hunter | Biotech Hunter